X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1191) 1191
male (1122) 1122
female (786) 786
animals (783) 783
pyridazines - administration & dosage (783) 783
pyridazines - pharmacology (756) 756
index medicus (755) 755
pyridazines - therapeutic use (645) 645
middle aged (512) 512
adult (432) 432
pharmacology & pharmacy (390) 390
rats (372) 372
aged (308) 308
pyridazines - adverse effects (276) 276
levosimendan (268) 268
treatment outcome (268) 268
dose-response relationship, drug (261) 261
hydrazones - administration & dosage (259) 259
pyridazines - pharmacokinetics (257) 257
hydrazones - therapeutic use (251) 251
heart failure - drug therapy (243) 243
cardiotonic agents - administration & dosage (239) 239
cardiotonic agents - therapeutic use (231) 231
cardiac & cardiovascular systems (228) 228
administration, oral (220) 220
mice (208) 208
blood pressure - drug effects (206) 206
hemodynamics - drug effects (196) 196
time factors (191) 191
heart failure (175) 175
cardiotonic agents - pharmacology (167) 167
heart rate - drug effects (158) 158
double-blind method (147) 147
hydrazones - pharmacology (147) 147
efficacy (142) 142
infusions, intravenous (141) 141
hiv infections - drug therapy (140) 140
drug therapy, combination (134) 134
dogs (132) 132
pharmacokinetics (132) 132
safety (124) 124
drug therapy (122) 122
research (122) 122
pyridazines - chemistry (112) 112
dobutamine (109) 109
calcium sensitizer (103) 103
heart failure - physiopathology (103) 103
rats, sprague-dawley (103) 103
neurosciences (101) 101
pyridazines - blood (101) 101
adolescent (98) 98
care and treatment (96) 96
drug interactions (96) 96
drug administration schedule (95) 95
double-blind (93) 93
analysis (91) 91
hypertension - drug therapy (91) 91
dosage and administration (89) 89
etravirine (89) 89
infectious diseases (89) 89
myocardial contraction - drug effects (89) 89
disease models, animal (88) 88
heart-failure (86) 86
pyridazines - metabolism (85) 85
anti-hiv agents - administration & dosage (84) 84
vasodilator agents - administration & dosage (82) 82
health aspects (81) 81
vasodilator agents - therapeutic use (80) 80
cilazapril (79) 79
oncology (78) 78
hypertension, pulmonary - drug therapy (76) 76
in vitro techniques (76) 76
young adult (75) 75
simendan (74) 74
chemistry, medicinal (73) 73
prospective studies (73) 73
pyridazines - chemical synthesis (73) 73
vasodilator agents - pharmacology (73) 73
follow-up studies (72) 72
hemodynamics (72) 72
injections, intravenous (72) 72
mortality (72) 72
cardiotonic agents - adverse effects (71) 71
therapy (71) 71
clinical trials as topic (69) 69
structure-activity relationship (69) 69
rats, wistar (68) 68
surgery (67) 67
medicine & public health (66) 66
aged, 80 and over (65) 65
anesthesiology (63) 63
hydrazones - adverse effects (63) 63
rats, inbred strains (63) 63
placebo-controlled trial (62) 62
ventricular function, left - drug effects (62) 62
research article (61) 61
heart (60) 60
anti-hiv agents - therapeutic use (59) 59
echocardiography (59) 59
imidazoles - administration & dosage (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1727) 1727
Japanese (32) 32
German (23) 23
Russian (16) 16
Spanish (13) 13
Italian (12) 12
French (9) 9
Chinese (4) 4
Norwegian (2) 2
Turkish (2) 2
Croatian (1) 1
Czech (1) 1
Lithuanian (1) 1
Polish (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NeuroImage, ISSN 1053-8119, 11/2016, Volume 141, pp. 10 - 17
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1547 - 1555
Journal Article
Cancer, ISSN 0008-543X, 12/2016, Volume 122, Issue 23, pp. 3650 - 3656
BACKGROUND The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been... 
dexamethasone (hyper‐CVAD [HCVAD]) | dasatinib | vincristine | acute lymphoblastic leukemia | hyperfractionated cyclophosphamide | ponatinib | doxorubicin | Philadelphia chromosome | dexamethasone (hyper-CVAD [HCVAD]) | ADULT PATIENTS | hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (hyper-CVAD [HCVAD]) | ACUTE LYMPHOCYTIC-LEUKEMIA | REGIMEN | PHASE-2 | CHEMOTHERAPY | ONCOLOGY | TERM-FOLLOW-UP | IMATINIB MESYLATE | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Prospective Studies | Humans | Middle Aged | Imidazoles - administration & dosage | Male | Survival Rate | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Young Adult | Disease-Free Survival | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Propensity Score | Dasatinib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyridazines - administration & dosage | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Aged | Philadelphia Chromosome - drug effects | Doxorubicin - administration & dosage | Dasatinib | Care and treatment | Dosage and administration | Acute lymphocytic leukemia | Diagnosis | Research | Comparative analysis | Chromosomes
Journal Article
International Journal of Hematology, ISSN 0925-5710, 11/2017, Volume 106, Issue 5, pp. 591 - 611
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s12185-017-2330-1 Byline:... 
Medicine & Public Health | Hematology | Oncology | RISK ESSENTIAL THROMBOCYTHEMIA | PLUS INTERFERON-ALPHA | DIAGNOSED CHRONIC-PHASE | COMPLETE MOLECULAR REMISSION | STANDARD-DOSE IMATINIB | TYROSINE KINASE INHIBITOR | PATIENTS RECEIVING IMATINIB | STEM-CELL TRANSPLANTATION | HEMATOLOGY | CHRONIC MYELOID-LEUKEMIA | INTERNATIONAL WORKING GROUP | Prognosis | Humans | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Risk | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Antineoplastic Agents - administration & dosage | Quinolines - administration & dosage | Myeloproliferative Disorders - genetics | Aspirin - administration & dosage | Nitriles - administration & dosage | Blood Transfusion | Pyridazines - administration & dosage | Quinazolines - administration & dosage | Aniline Compounds - administration & dosage | Myeloproliferative Disorders - therapy | Pyrimidines - administration & dosage | Japan | Myeloproliferative Disorders - classification | Phlebotomy | Hematopoietic Stem Cell Transplantation | Hydroxyurea - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - classification | Pyrazoles - administration & dosage | Algorithms | Dasatinib - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Tumors | Myeloid leukemia | Leukemia | Chronic myeloid leukemia | Lymphoid tissue | Tissues | Neoplasms | Hemopoiesis
Journal Article
Hepatology, ISSN 0270-9139, 07/2014, Volume 60, Issue 1, pp. 56 - 64
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2017, Volume 243, pp. 389 - 395
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 03/2007, Volume 27, Issue 10, pp. 2718 - 2726
We describe a novel corticotropin- releasing factor receptor 1 ( CRF1) antagonist with advantageous properties for clinical development, and its in vivo... 
Self-administration | Relapse | Drug seeking | Alcoholism | CRF | Stress | stress | relapse | CENTRAL NUCLEUS | drug seeking | ANXIETY-LIKE BEHAVIOR | NEUROSCIENCES | ETHANOL-DEPENDENT RATS | POTENT | alcoholism | self-administration | REINSTATEMENT | HYDROCHLORIDE SSR125543A | SEEKING BEHAVIOR | WITHDRAWAL | Peptides - antagonists & inhibitors | Pituitary Gland - metabolism | Rats, Wistar | Alcohol Drinking - psychology | Cerebellum - drug effects | Ethanol - administration & dosage | Male | Thiazoles - administration & dosage | Thiazoles - therapeutic use | Thiazoles - pharmacokinetics | Brain - metabolism | Dose-Response Relationship, Drug | Peptide Hormones | Self Administration | Peptides - metabolism | Pyridazines - administration & dosage | Behavior, Animal - drug effects | Alcoholism - psychology | Pyridazines - therapeutic use | Disease Models, Animal | Amphibian Proteins | Administration, Oral | Cerebellum - metabolism | Anxiety - psychology | Rats | Rats, Sprague-Dawley | Animals | Receptors, Corticotropin-Releasing Hormone - antagonists & inhibitors | Alcoholism - genetics | Pyridazines - pharmacokinetics | Alcoholism - drug therapy | Stress, Physiological - psychology | Substance Withdrawal Syndrome - psychology | Pituitary Gland - drug effects | Basic Medicine | Neurosciences | Medical and Health Sciences | alcoholism; drug seeking; self-administration; relapse; stress; CRF | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | Neurovetenskaper
Journal Article
Journal of Aerosol Medicine and Pulmonary Drug Delivery, ISSN 1941-2711, 06/2016, Volume 29, Issue 3, pp. 233 - 241
Background: In allergen-induced asthma, activated mast cells start the lung inflammatory process with degranulation, cytokine synthesis, and mediator release.... 
pharmacokinetics | jet mill | dust feed | lung function | inhaled therapy | pre-clinical | LUNG | ACTIVATION | LATE RESPONSES | DEPOSITION | RATS | BRUTONS TYROSINE KINASE | INTRATRACHEAL INSTILLATION | INTERNALIZATION | RESPIRATORY SYSTEM | MICE | MAST-CELL DEGRANULATION | Glucocorticoids - administration & dosage | Pneumonia - physiopathology | Bronchial Hyperreactivity - immunology | Bronchodilator Agents - administration & dosage | Protein-Tyrosine Kinases - metabolism | Humans | Male | Lung - enzymology | Bronchoconstriction - drug effects | Asthma - immunology | Pneumonia - immunology | Anti-Inflammatory Agents - administration & dosage | Disease Models, Animal | Protein Kinase Inhibitors - pharmacokinetics | Dry Powder Inhalers | Phthalazines - administration & dosage | Asthma - physiopathology | Pneumonia - enzymology | Asthma - enzymology | Lung - physiopathology | Mast Cells - enzymology | Protein Kinase Inhibitors - administration & dosage | B-Lymphocytes - immunology | Lung - drug effects | Pyridazines - pharmacokinetics | Mice, Inbred BALB C | Budesonide - administration & dosage | Immunoglobulin G - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Phthalazines - pharmacokinetics | Pneumonia - prevention & control | Dose-Response Relationship, Drug | Anti-Asthmatic Agents - pharmacokinetics | Immunoglobulin G - immunology | Prostaglandin D2 - metabolism | Bronchial Hyperreactivity - physiopathology | Albuterol - administration & dosage | Pyridazines - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Cytokines - immunology | Mast Cells - immunology | Ovalbumin | B-Lymphocytes - enzymology | Cytokines - metabolism | Cells, Cultured | Administration, Inhalation | Bronchial Hyperreactivity - prevention & control | Asthma - drug therapy | Mast Cells - drug effects | B-Lymphocytes - drug effects | Bronchial Hyperreactivity - enzymology | Animals | Bronchodilator Agents - pharmacokinetics | Prostaglandin D2 - immunology | Adrenergic beta-2 Receptor Agonists - administration & dosage | Anti-Asthmatic Agents - administration & dosage | Lung - immunology | Cell Degranulation - drug effects
Journal Article
European Respiratory Journal, ISSN 0903-1936, 06/2016, Volume 47, Issue 6, pp. 1727 - 1736
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 22, pp. 2075 - 2088
Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | KINASE DOMAIN MUTATIONS | DIAGNOSED CHRONIC-PHASE | TYROSINE KINASE | INTERNATIONAL-WORKING-GROUP | FOLLOW-UP | CLINICAL RESISTANCE | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | Amylases - blood | Lipase - blood | Follow-Up Studies | Humans | Middle Aged | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Pyridazines - adverse effects | Imidazoles - adverse effects | Antineoplastic Agents - chemistry | Pancreatitis - chemically induced | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Patient outcomes | BCR-ABL tyrosine kinase inhibitors | Dosage and administration | Genetic aspects | Acute lymphocytic leukemia | Research | Drug therapy | Tyrosine | BCR protein | Acute lymphatic leukemia | Myeloid leukemia | Leukemia | Pancreatitis | Abl protein | Chronic myeloid leukemia | Lymphatic leukemia | Lipase | Kinases | Philadelphia chromosome | Proteins | Myelosuppression | Fusion protein | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Infection, ISSN 0163-4453, 2008, Volume 57, Issue 1, pp. 1 - 10
Summary Since 1996, the prognosis of those living with HIV and AIDS has improved significantly due to highly active antiretroviral therapy (HAART). Treatment... 
Infectious Disease | Tipranavir | Darunavir | Maraviroc | Etravirine | Salvage therapy | Raltegravir | INFECTIOUS DISEASES | maraviroc | UNITED-KINGDOM | EFFICACY | SAFETY | tipranavir | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | etravirine | DRUG-RESISTANCE | PROTEASE INHIBITORS | DOUBLE-BLIND | darunavir | INFECTION | PLACEBO-CONTROLLED TRIAL | salvage therapy | rattegravir | Triazoles - administration & dosage | Humans | Salvage Therapy | Cyclohexanes - administration & dosage | HIV Integrase Inhibitors - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Cyclohexanes - therapeutic use | HIV Fusion Inhibitors - administration & dosage | Pyridazines - administration & dosage | Anti-HIV Agents - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | Raltegravir Potassium | Pyridazines - therapeutic use | CCR5 Receptor Antagonists | Pyridines - therapeutic use | Triazoles - therapeutic use | Pyridines - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Pyrrolidinones - therapeutic use | Treatment Outcome | Clinical Trials as Topic | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Pyrones - administration & dosage | HIV Fusion Inhibitors - therapeutic use | Sulfonamides - therapeutic use | HIV Integrase Inhibitors - therapeutic use | Pyrones - therapeutic use | HIV Infections - drug therapy | Sulfonamides - administration & dosage | Highly active antiretroviral therapy | Antiviral agents | Reverse transcriptase | Protease inhibitors | Proteases | HIV patients | HIV (Viruses) | Drug therapy | Drug resistance | HIV infection | Anti-HIV agents
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 04/2014, Volume 54, Issue 4, pp. 422 - 431
Journal Article